Using AI to Fight Cancer | Idea Exchange | Jane King & Selin Kurnaz
Using AI to Fight Cancer | Idea Exchange | Jane King & Selin Kurnaz
Interview by Jane King – New York Stock Exchange
Massive Bio co-founder and CEO Selin Kurnaz joined Jane King on the floor of the New York Stock Exchange to discuss how the company’s AI-powered platform is transforming cancer care, giving patients worldwide scalable, equitable access to clinical trials and accelerating drug development.
Jane King: I’m with Selin, the co-founder and CEO of Massive Bio. Welcome to the floor of the New York Stock Exchange. Explain a little bit about what is it exactly that Massive Bio is doing?
Selin Kurnaz: Massive Bio is a company that transforms how cancer patients get access to clinical trials. I founded Massive Bio based on my family’s frustration in cancer care. Massive Bio is building the world’s largest AI-driven real-time foundational model in cancer to improve clinical trial access for individual cancer patients, and also using those cancer patient journeys as a catalyst for better drug development and discovery.
Jane King: So explain the new platform that you’re using, the AI-driven platform.
Selin Kurnaz: A couple of weeks ago, Massive Bio launched the world’s first full agentic AI-driven patient journey, which we call Reticulum Nexus. Reticulum Nexus is a combination of specialized agents and orchestrators. What that brings is that this is the first time in the world of cancer there is scalability coming directly to patients, so that patients are becoming almost like consumers. They can activate their clinical trial access anywhere in the world, efficiently and at scale. I’m so proud that Massive Bio is championing that journey through the advancement and augmentation of artificial intelligence.
Jane King: So what does success look like for Massive Bio?
Selin Kurnaz: Cancer is smart and it fights very well. What we want to do is eradicate cancer from the map and make sure that every cancer patient, from the moment they are diagnosed, has the ability to access clinical trials through the advancement of technology – no matter where they are located or what their financial status is. This is the democratization of clinical trial access for every cancer patient in the world.
But it is clear that this cannot be done by just one company or one individual. We invite everyone to consolidate around this common goal, augment technology, scale it, and put it at the disposal of cancer patients to improve their lives.
Jane King: Selin, thank you so much for joining us here at the New York Stock Exchange and telling us all about Massive Bio.
Selin Kurnaz: Thank you very much, Jane, for having me. It was a wonderful interview.